<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1383765F-BE9A-4E31-AEFB-8EA2FFE433A1"><gtr:id>1383765F-BE9A-4E31-AEFB-8EA2FFE433A1</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:surname>Rittman</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100464"><gtr:id>E9D2881D-C3D8-418C-A258-788BD93A07F7</gtr:id><gtr:title>Functional Brain Connectivity in Neurodegenerative Tauopathy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1100464</gtr:grantReference><gtr:abstractText>Many dementias have build-up of junk proteins in brain cells that stop them functioning. Junk proteins affect some brain regions more than others resulting in damaged connections between brain cells. Connections can be measured using two scanning techniques looking at oxygen demands (MRI) or electrical activity (MEG). 

We will use both scan types on resting subjects. Scans will be analysed using graph theory, a mathematical model describing network behaviour. Graph theory principles have been applied to many networks, from the internet to social groups. Different effects on connectivity will tell us about the spread and selectivity of disease processes.

Tau is a protein of particular importance in brain diseases including Alzheimer?s and Parkinson?s disease. The rare condition progressive supranuclear palsy is a simpler tau disorder; a good place to start studying its effect on brain networks. We will identify patterns of functional connectivity that are signatures of tau. We will then look at another dementia where tau accumulation is found called corticobasal degeneration.

Our results could be used to develop markers of disease progression for drug trials. It may help differentiate between dementias and there is a possibility that new drugs targeting abnormalities in networks could be developed.</gtr:abstractText><gtr:technicalSummary>We will develop network-based imaging analysis of tau-associated neurodegenerative disease, bridging the gap between cellular and clinical phenotypic analysis and enabling networking approaches to characterise disease patterns. Our hypothesis is that specific patterns of progression of tau protein aggregation and cell death are associated with characteristic functional brain connectivity disturbances. Selective vulnerability of neural networks and mode of network disruption underlie specific clinical features.

We predict graph theory metrics of magnetic resonance images and magnetoencephalography will reveal reduced network efficiency. Importantly, different candidate mechanisms of disease progression predict contrasting graph metrics results. For example, selective vulnerability of neuronal subpopulations to oxidative stress suggests highly connected hub areas would be most affected. In contrast, prion-like spread predicts contiguous reduction in measures of network efficiency and clustering.

Although the tauopathy progressive supranuclear palsy is relatively uncommon, it has advantages of high clinicopathological correlation and relatively discrete molecular pathology. Insights gained from this prototypical tauopathy will translate to a range of neurodegenerative diseases including Alzheimer?s, Pick?s and Parkinson?s disease.

Our objectives are to:
1. analyse resting state functional magnetic resonance imaging data of patients with progressive supranuclear palsy using graph theory metrics.
2. analyse resting state magnetoencephalography data of patients with progressive supranuclear palsy in the same way; compare results with fMRI data; contrast pathological changes in network function at different frequency ranges.
3. apply these techniques to other neurodegenerative disorders with tau-based pathology, including corticobasal degeneration.

An existing patient cohort will be supplemented by new cases, scanned using 3-Tesla EPI-fMRI at rest for utes. Optimised structural MPRAGE and DWI images will be acquired concurrently but this project focuses on analysis of functional networks. A subset of cases will undergo magnetoencephalography (Elekta Neuromag 406). Analysis will focus on metrics of functional connectivity using techniques developed in part by my second supervisor (Bullmore).

The study will lead to a new model of tau-mediated neurodegeneration described by dynamic interactions among distributed brain networks. This approach helps understand clinical features such as dementia, apathy and imbalance which are difficult to ascribe to focal neurodegeneration.

New features this method are: (a) joint applicability to fMRI and MEG, capturing frequency dependent and independent signals, (b) detecting effects of disease in hub regions, local clusters and their interconnections and relating these to models of disease progression (c) Like covariance-based analyses of functional connectivity, we expect high disease sensitivity, important for any potential surrogate marker of disease modification.</gtr:technicalSummary><gtr:fund><gtr:end>2014-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>189527</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>PSP Association Professionals day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>37467D54-CC4D-4AA7-98F6-AF5B452ACBD0</gtr:id><gtr:impact>I attended a study day for health professionals organised by the PSP Assocation for those involved in the care of people with the two disorders I am investigating; Progressive Supranuclear Palsy and Corticobasal Degeneration. I was able to discuss my research with frontline health and social care staff, members and employees of the PSP Association and colleagues from other institutions around the country.

I was able to raise awareness about the research that is going on in these diseases, and further plans for collaboration between institutions with cohorts of PSP and CBD patients.</gtr:impact><gtr:outcomeId>DANviXtbZG5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Local PSP support group</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>873E0D4E-48B6-4789-B29F-EB693338C0B6</gtr:id><gtr:impact>I attended and supported the setting up of a local support group for people with Progressive Supranuclear Palsy and Corticobasal Degeneration. This was attended by patients and their carers.

A number of people expressed and interest in participating in research programmes. I was able to direct them either to our own researhc programmes or those at other institutions in the region.</gtr:impact><gtr:outcomeId>MtkPiSKqZL2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>750</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Association of British Neurologists Travel Grant</gtr:description><gtr:end>2012-11-02</gtr:end><gtr:fundingOrg>Association of British Neurologists (ABN)</gtr:fundingOrg><gtr:id>9B88DC2C-4B27-4C14-B87B-74232F964A41</gtr:id><gtr:outcomeId>ZZNfvFNfPKS</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Travel Grant</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>Guarantors of Brain</gtr:fundingOrg><gtr:id>F1DC377B-1B19-4CA9-9802-B4621E153595</gtr:id><gtr:outcomeId>KQfm346dLPW</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Input to Care Pathway for Progressive Supranuclear Palsy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>45CEF596-6787-43B6-8B70-E8CD8C902494</gtr:id><gtr:impact>The pathway for care of PSP patients has enabled case-by-case improvement in early access to appropriate services for patients with a challenging and unusual form of dementia.</gtr:impact><gtr:outcomeId>AgSWcykddRy</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type><gtr:url>http://www.pspassociation.org.uk/for-professionals/care-pathway-guide/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>A python package for analysis and visualisation of connectivity in neuroimaging data.</gtr:description><gtr:id>8DB311F9-CAB7-48D0-8BFC-DDDB039B700A</gtr:id><gtr:impact>The software has accelerated imaging analysis and enabled connections between different types of data, such as gene expression data from the Allen brain atlas and neuroimaging data.</gtr:impact><gtr:outcomeId>545bef9db1abf4.27242012</gtr:outcomeId><gtr:title>Maybrain</gtr:title><gtr:type>Software</gtr:type><gtr:url>https://github.com/rittman/maybrain</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>488855B0-0BD5-4E22-A9B4-651272397D0A</gtr:id><gtr:title>Improving response inhibition in Parkinson's disease with atomoxetine.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0737230de95b4af7036a0056f2039d97"><gtr:id>0737230de95b4af7036a0056f2039d97</gtr:id><gtr:otherNames>Ye Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>doi_55f985985b245035</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3230F28-7F07-46B5-AED3-4F41273D12D4</gtr:id><gtr:title>Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5f0442ffcdcd359cb84f7e73b5cdf13"><gtr:id>a5f0442ffcdcd359cb84f7e73b5cdf13</gtr:id><gtr:otherNames>Rittman T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>585d34e342d485.78603720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A4C2757-2B8F-418F-A61F-CAC26C915533</gtr:id><gtr:title>Validation of the new consensus criteria for the diagnosis of corticobasal degeneration.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55ed361343234941f09662a6c7232d8f"><gtr:id>55ed361343234941f09662a6c7232d8f</gtr:id><gtr:otherNames>Alexander SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>545bea537acf32.81056110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0B94061-525F-46E6-9A86-A0677F504FEE</gtr:id><gtr:title>Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dab3a52525a13cb27fc9cf7d9b96ed74"><gtr:id>dab3a52525a13cb27fc9cf7d9b96ed74</gtr:id><gtr:otherNames>M?ller U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>pm_13924_24_22820554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B358787C-0E83-4188-BA2A-2BB238DAD6EE</gtr:id><gtr:title>Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0737230de95b4af7036a0056f2039d97"><gtr:id>0737230de95b4af7036a0056f2039d97</gtr:id><gtr:otherNames>Ye Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>545bea53a48bc2.69652046</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F0D71E0-649E-47A7-A545-B0CBCDE199EA</gtr:id><gtr:title>Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4ff7a6b651951cf08e01f94a1151283"><gtr:id>f4ff7a6b651951cf08e01f94a1151283</gtr:id><gtr:otherNames>Passamonti L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5a9faa5a8e5dd9.22379064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>013B299C-A92C-43D0-8750-EE5AA8228B65</gtr:id><gtr:title>Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18d6ceb7e456b3ded1c14f96544ea7a5"><gtr:id>18d6ceb7e456b3ded1c14f96544ea7a5</gtr:id><gtr:otherNames>Borchert RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>5a9faa5ab23cc8.13694367</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD7BCA1A-B981-4EAA-BA9B-FD212BDC7504</gtr:id><gtr:title>Gene transcription profiles associated with inter-modular hubs and connection distance in human functional magnetic resonance imaging networks.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db3c12d34f4263254332a380aaf89d5b"><gtr:id>db3c12d34f4263254332a380aaf89d5b</gtr:id><gtr:otherNames>V?rtes PE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>5a9faa5b1b8a04.32212376</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>279CDF5D-3C0A-40BB-B987-8694048F34FC</gtr:id><gtr:title>Managing cognition in progressive supranuclear palsy.</gtr:title><gtr:parentPublicationTitle>Neurodegenerative disease management</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5f0442ffcdcd359cb84f7e73b5cdf13"><gtr:id>a5f0442ffcdcd359cb84f7e73b5cdf13</gtr:id><gtr:otherNames>Rittman T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1758-2024</gtr:issn><gtr:outcomeId>588b6b4e7dbd98.55401969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1F7D61E-3526-42DE-BEFF-4CDD1AC798B3</gtr:id><gtr:title>Multiple modes of impulsivity in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd26b1e138b12e934f0f4bc35f2a04be"><gtr:id>cd26b1e138b12e934f0f4bc35f2a04be</gtr:id><gtr:otherNames>Nombela C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_540e17be17b2bc3e4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24D2D50D-CBCE-44EA-8EF1-0992F614C15A</gtr:id><gtr:title>Transcriptional data: a new gateway to drug repositioning?</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94de37228266c4739326bf206eeb5566"><gtr:id>94de37228266c4739326bf206eeb5566</gtr:id><gtr:otherNames>Iorio F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>pm_13924_24_22897878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F25DB994-42BB-4715-B2DD-09AABAC06FC9</gtr:id><gtr:title>Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f5ff2310b21823fdc45326aba6a7d2d"><gtr:id>6f5ff2310b21823fdc45326aba6a7d2d</gtr:id><gtr:otherNames>Zhang J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>585d6a77bb4522.85776380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9A95606-4FBE-4362-AE74-F51DDA2A3CB5</gtr:id><gtr:title>The medial frontal-prefrontal network for altered awareness and control of action in corticobasal syndrome.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f2283d5c278f46275ac6315bd01fca7"><gtr:id>7f2283d5c278f46275ac6315bd01fca7</gtr:id><gtr:otherNames>Wolpe N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>545bea540107e5.97778577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15A6802F-F7FF-429B-A817-153245E64B27</gtr:id><gtr:title>The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5f0442ffcdcd359cb84f7e73b5cdf13"><gtr:id>a5f0442ffcdcd359cb84f7e73b5cdf13</gtr:id><gtr:otherNames>Rittman T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_13924_24_23303961</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66030D4B-9DFE-4A21-98B9-EC8F41B5D727</gtr:id><gtr:title>Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7739cf3922211f1061792fc3fe057fa7"><gtr:id>7739cf3922211f1061792fc3fe057fa7</gtr:id><gtr:otherNames>Cope TE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5a9faa5a604488.43601964</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100464</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>